Results 1 to 10 of about 47,525 (299)

Rapid Detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 Alleles by Tetra-Primer PCR and of the CYP2D6*5 Allele by Multiplex Long PCR [PDF]

Clinical Chemistry, 2000
Abstract Background: Interindividual differences in CYP2D6 activity range from total absence of metabolism of certain drugs to ultrafast metabolism and can produce adverse effects or lack of therapeutic effect under standard therapy. Several mutations have been described in the CYP2D6 gene that abolish CYP2D6 activity.
Martin Hersberger, Jacqueline Marti-Jaun, Katharina Rentsch, Edgar Hänseler   +3 more
openalex   +4 more sources

Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders [PDF]

BMC Pediatrics
Background Aripiprazole (ARI) is the first-line treatment for tic disorders (TD). Cytochrome P450(CYP)2D6 (CYP2D6) and ATP-binding cassette, sub-family B, member 1 (ABCB1) transporter are involved in the metabolism of ARI.
Yingying Xin, Liuliu Gao, Sichan Li, Jun Wang, Chen Chen, Yali Tuo, Gang Nie, Ruizhen Li, Dan Sun, Yongli Fu, Yang Wang, Zhisheng Liu   +11 more
doaj   +2 more sources

Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations [PDF]

Pharmacia, 2021
Wild type genotypes (CYP2D6) and their allelic variants have been described in a sample of a Peruvian mestizo population. The global allele frequency was 0.015 for CYP2D6*3 and 0.051 for CYP2D6*4. The percentages of genotypes described were 97% CYP2D6*1/*
Angel T. Alvarado, Roberto Ybañez-Julca, Ana María Muñoz, César Tejada-Bechi, Roberto Cerro, Luis Abel Quiñones, Nelson Varela, César André Alvarado, Erick Alvarado, María R. Bendezú, Jorge A. García   +10 more
doaj   +3 more sources

In vitro study on the effect of peucedanol on the activity of cytochrome P450 enzymes

Pharmaceutical Biology, 2021
Context Peucedanol is a major extract of Peucedanum japonicum Thunb. (Apiaceae) roots, which is a commonly used herb in paediatrics. Its interaction with cytochrome P450 enzymes (CYP450s) would lead to adverse effects or even failure of therapy ...
Cun Zhang, Yongwei Li, Changlong Yin, Jie Zheng, Guozhi Liu   +4 more
doaj   +1 more source

The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva

Frontiers in Pharmacology, 2022
Aims: The CYP2D6*41 variant is the second or third frequent reduced function allele in Chinese with a frequency of around 3–4%, while it is the major reduced function allele in Indians, Saudi Arabians and Caucasians with frequencies of around 10–20%. The
Ye Jin, Shuquan Zhang, Pei Hu, Xin Zheng, Xiaoduo Guan, Rui Chen, Shuyang Zhang   +6 more
doaj   +1 more source

Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6 [PDF]

Xenobiotica, 2013
1. Metoclopramide is a widely used clinical drug in a variety of medical settings with rare acute dystonic events reported. The aim of this study was to assess a previous report of inactivation of CYP2D6 by metoclopramide, to determine the contribution of various CYPs to metoclopramide metabolism, and to identify the mono-oxygenated products of ...
Mara Livezey, Leslie D. Nagy, Erran D. Briggs, Amanda K. Bolles, Laura Lowe Furge, Rina Fujiwara   +5 more
openaire   +3 more sources

Is CYP2D6 phenotype predictable from CYP2D6 genotype? [PDF]

Microchemical Journal, 2018
Abstract Genetic polymorphism of cytochrome P450s results in clinically significant modifications in patients' drug metabolizing capacities. CYP2D6 has a crucial role in the elimination of several clinically important drugs (antiarrhythmics, beta-adrenergic blockers, psychopharmacons and analgesics); however, the prediction of the phenotypic ...
Ádám Ferenc Kiss, Katalin Tóth, Cintia Juhász, Manna Temesvári, József Paulik, Gábor Hirka, Katalin Monostory   +6 more
openaire   +3 more sources

Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine

CPT: Pharmacometrics & Systems Pharmacology, 2021
The cytochrome P450 (CYP) 2D6 enzyme exhibits large interindividual differences in metabolic activity. Patients are commonly assigned a CYP2D6 phenotype based on their CYP2D6 genotype, but there is a lack of consensus on how to translate genotypes into ...
Trine Frederiksen, Johan Areberg, Ellen Schmidt, Tore Bjerregaard Stage, Kim Brøsen   +4 more
doaj   +1 more source

Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan [PDF]

Clinical Pharmacology & Therapeutics, 2010
The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms. The aim of this study was to quantify the effects of the CYP2D6*1, *2, and *41 variants on DM metabolism in vivo and to identify other sources of pharmacokinetic variability.
Uwe Fuhr, Tobias Klaassen, Khaled Abduljalil, Julia Kirchheiner, Alexander Jetter, Alexander Jetter, Dorota Tomalik-Scharte, Andrea Gaedigk, Ulrich Jaehde, D Frank   +9 more
openaire   +4 more sources

Does ethnicity impact CYP2D6 genotype–phenotype relationships?

Clinical and Translational Science, 2023
Polymorphism of the CYP2D6 gene leads to substantial interindividual variability in CYP2D6 enzyme activity. Despite improvements in prediction of CYP2D6 activity based on genotype information, large interindividual variability within CYP2D6 genotypes ...
Trine Frederiksen, Johan Areberg, Ellen Schmidt, Tore Bjerregaard Stage, Kim Brøsen   +4 more
doaj   +1 more source